Inventor · disambiguated record
Zhongyu Zhu
Also filed as: ZHU ZHONGYU
50 granted patents·13 pending applications·224 citations·filing 2007–2024
98Inventor score
Files withLENTIGEN TECH INC20US HEALTH14BIOMED VALLEY DISCOVERIES INC8CHILDRENS HOSPITAL PHILADELPHIA3DIMITROV DIMITER S3
Top patents by PatentIndex Score
63 records- 0197US10844128B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Nov 24, 2020·20 cites·11 claims
- 0297US10428141B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·15 cites·13 claims
- 0396US10183993B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 22, 2019·11 cites·27 claims
- 0496US9790282B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsUS HEALTH·Filed 2014·Granted Oct 17, 2017·28 cites·29 claims
- 0596US9765142B2TEM8 antibodies and their use in treatment and detection of tumorsUS HEALTH·Filed 2014·Granted Sep 19, 2017·31 cites·49 claims
- 0695US10543263B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2018·Granted Jan 28, 2020·14 cites·12 claims
- 0795US10501539B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Dec 10, 2019·8 cites·6 claims
- 0895US10426797B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·19 cites·10 claims
- 0994US8313746B2Human monoclonal antibodies against hendra and nipah virusesDIMITROV DIMITER S·Filed 2011·Granted Nov 20, 2012·12 cites·14 claims
- 1093US11103533B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Aug 31, 2021·7 cites·13 claims
- 1193US10550179B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Feb 4, 2020·6 cites·18 claims
- 1292US11052112B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 6, 2021·5 cites·9 claims
- 1392US9738726B2HER2-specific monoclonal antibodies and conjugates thereofUS HEALTH·Filed 2014·Granted Aug 22, 2017·12 cites·32 claims
- 1489US10548987B2Antibody-drug conjugates for targeting CD56-positive tumorsUS HEALTH·Filed 2016·Granted Feb 4, 2020·8 cites·16 claims
- 1588US11590169B1Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Feb 28, 2023·2 cites·20 claims
- 1688US10604582B2Anti-CD276 antibodies (B7H3)THE US SECRETARY DEPARTMENT OF HEALTH·Filed 2015·Granted Mar 31, 2020·4 cites·37 claims
- 1787US11453719B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Sep 27, 2022·2 cites·19 claims
- 1886US10758614B2Combination therapies targeting tumor-associated stroma or tumor cells and topoisomeraseBIOMED VALLEY DISCOVERIES INC·Filed 2015·Granted Sep 1, 2020·3 cites·10 claims
- 1985US8071323B2Human monoclonal antibodies that bind human insulin like growth factors and their useDIMITROV DIMITER S·Filed 2007·Granted Dec 6, 2011·8 cites·52 claims
- 2082US11878052B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2020·Granted Jan 23, 2024·1 cites·19 claims
- 2182US11078286B2Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their useUS HEALTH·Filed 2016·Granted Aug 3, 2021·2 cites·9 claims
- 2282US2025101088A1Monoclonal antibodies that specifically bind to matrilin 3 and their useUS HEALTH·Filed 2024·Application pending·0 cites
- 2381US11464801B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Oct 11, 2022·1 cites·15 claims
- 2480US2023331832A1Monoclonal antibodies that specifically bind to matrilin 3 and their useUS HEALTH·Filed 2023·Application pending·0 cites
- 2580US2024067724A1Compositions and Methods for Treating Cancer with Anti-CD19 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2679US2024108706A1Compositions and Methods for Treating Cancer with Anti-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2779US2023110875A1Anti-cd276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH·Filed 2022·Application pending·0 cites
- 2877US10604583B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2017·Granted Mar 31, 2020·1 cites·22 claims
- 2977US8858938B2Human monoclonal antibodies against Hendra and Nipah virusesJACKSON H M FOUND MILITARY MED·Filed 2013·Granted Oct 14, 2014·1 cites·2 claims
- 3076US9150644B2Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and IIDIMITROV DIMITER S·Filed 2012·Granted Oct 6, 2015·2 cites·27 claims
- 3175US11708408B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jul 25, 2023·0 cites·17 claims
- 3274US11814440B2Glypican 2 as a cancer marker and therapeutic targetCHILDRENS HOSPITAL PHILADELPHIA·Filed 2016·Granted Nov 14, 2023·1 cites·14 claims
- 3374US2023241103A1Compositions and Methods for Treating Cancer with Anti-CD33 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 3472US12453780B2Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their useUS HEALTH·Filed 2021·Granted Oct 28, 2025·0 cites·20 claims
- 3572US12037403B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Jul 16, 2024·0 cites·8 claims
- 3672US11680093B2Monoclonal antibodies that specifically bind to matrilin 3 and their useUS HEALTH·Filed 2021·Granted Jun 20, 2023·0 cites·40 claims
- 3771US12391958B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·21 claims
- 3871US12391740B2Compositions and methods for treating cancer with anti-BCMA immunotherapyLENTIGEN TECH INC·Filed 2021·Granted Aug 19, 2025·0 cites·23 claims
- 3970US2024084034A1Glypican 2 as a cancer marker and therapeutic targetCHILDRENS HOSPITAL PHILADELPHIA·Filed 2023·Application pending·0 cites
- 4069US11512138B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2020·Granted Nov 29, 2022·0 cites·20 claims
- 4168US11970528B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Apr 30, 2024·0 cites·18 claims
- 4268US2015071854A1Human Monoclonal Antibodies Against Hendra and Nipah VirusesJACKSON H M FOUND MILITARY MED·Filed 2014·Application pending·0 cites
- 4367US11851498B2Anti-CD276 antibodies (B7H3)THE US SECRETARY DEPARTMENT OF HEALTH·Filed 2020·Granted Dec 26, 2023·0 cites·20 claims
- 4466US10954291B2Monoclonal antibodies that specifically bind to matrilin-3 and their useTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES THE GOVERNMENT·Filed 2019·Granted Mar 23, 2021·0 cites·36 claims
- 4563US2013149246A1Human Monoclonal Antibodies Against Hendra and Nipah VirusesJACKSON H M FOUND MILITARY MED·Filed 2012·Application pending·0 cites
- 4661US11939377B2Affinity matured CD22-specific monoclonal antibody and uses thereofUS HEALTH·Filed 2019·Granted Mar 26, 2024·0 cites·35 claims
- 4760US10323083B2Agents that specifically bind matrilin-3 and their useUS HEALTH·Filed 2015·Granted Jun 18, 2019·0 cites·98 claims
- 4860US10196443B2TEM8 antibodies and their use in treatment and detection of tumorsUS HEALTH·Filed 2017·Granted Feb 5, 2019·0 cites·33 claims
- 4959US11389480B2Human monoclonal antibody targeting TNFR2 for cancer immunotherapyUS HEALTH·Filed 2018·Granted Jul 19, 2022·0 cites·41 claims
- 5059US9676846B2Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and IIUS HEALTH·Filed 2015·Granted Jun 13, 2017·0 cites·28 claims
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Zhongyu Zhu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →